Holen Sie sich die Stockscreener-App
200.69
2.01%
-4.11
Handel nachbörslich:
201.00
0.31
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$204.80
Offen:
$202.81
24-Stunden-Volumen:
1.08M
Relative Volume:
0.29
Marktkapitalisierung:
$311.24B
Einnahmen:
$58.80B
Nettoeinkommen (Verlust:
$10.24B
KGV:
61.21
EPS:
3.2788
Netto-Cashflow:
$8.98B
1W Leistung:
-0.77%
1M Leistung:
+9.31%
6M Leistung:
+139.29%
1J Leistung:
+196.92%
1-Tages-Spanne:
$200.67
$203.37
1-Wochen-Bereich:
$199.50
$205.30
52-Wochen-Spanne:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Lobbying Update: $2,280,000 of ASTRAZENECA PHARMACEUTICALS LP lobbying was just disclosed - Quiver Quantitative
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to drive sustained ups - AD HOC NEWS
AstraZeneca stock slips as weak momentum limits further upside - Traders Union
AstraZeneca (AZN) Achieves Success in Late-Stage COPD Trial for Tozorakimab - GuruFocus
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare‑ups - Reuters
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca Builds COPD Case For Tozorakimab With Third Positive Phase III Trial - Citeline News & Insights
Generic Injectables Market Major PlayersAstrazeneca, Baxter - openPR.com
AstraZeneca (AZN) Stock: Tozorakimab Achieves Phase III COPD Success in MIRANDA Study - Blockonomi
AstraZeneca (AZN) Stock: COPD Drug Tozorakimab Hits Phase III Trial Goals - CoinCentral
AstraZeneca (AZN) scores third positive Phase III COPD result for tozorakimab - Stock Titan
COPD patients saw fewer flare-ups in AstraZeneca's third Phase III trial - Stock Titan
Astrazeneca Says Tozorakimab Significantly Lowers COPD in Phase 3 Study - marketscreener.com
AstraZeneca's Tozorakimab meets primary endpoint in "pivotal" trial - marketscreener.com
AstraZeneca reports positive top-line data from Phase III MIRANDA trial - Sharecast.com
Astrazeneca says tozorakimab meets primary endpoint in phase III Miranda trial for COPD - marketscreener.com
AstraZeneca's tozorakimab delivers reduction in chronic lung disease flare-ups - marketscreener.com
AstraZeneca Reports Positive Late-stage Data for Chronic Obstructive Pulmonary Disease Drug Tozorakimab - marketscreener.com
AstraZeneca PLC stock (US6549022043): Is its oncology pipeline strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca's tozorakimab delivers sharp reduction in COPD flare-ups - marketscreener.com
AstraZeneca : Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD - marketscreener.com
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained upside? - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Is its oncology dominance strong enough to unlock new upside? - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): Is oncology dominance strong enough to drive sustained U.S. in - AD HOC NEWS
AstraZeneca’s Danicopan Korea Study: Real-World Data That Could Shape AZN’s Rare Disease Edge - TipRanks
AstraZeneca PLCdepositary receipt (AZN) price target increased by 107.33% to 202.76 - MSN
Mirae Asset Global Investments Co. Ltd. Acquires 42,665 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
AZN Stock Quote Price and Forecast - CNN
AST Large-Cap Value Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca stock holds steady after Assetmark Inc. and Pursuit Wealth buy shares - Traders Union
Astrazeneca Plc $AZN Shares Sold by Iams Wealth Management LLC - MarketBeat
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by Pr - GuruFocus
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
AstraZeneca (AZN) Advances Portfolio with Strategic Update - GuruFocus
AstraZeneca (AZN) Faces Rising Drug Prices Amid Senate Scrutiny - GuruFocus
Pursuit Wealth Management LLC Takes Position in Astrazeneca Plc $AZN - MarketBeat
Assetmark Inc. Buys 25,004 Shares of Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance Australia
AstraZeneca stock holds steady after $191 million grant for Albemarle facility approved - Traders Union
ZWJ Investment Counsel Inc. Lowers Holdings in Astrazeneca Plc $AZN - MarketBeat
Bingham Private Wealth LLC Takes $669,000 Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca plc stock (GB0009895292): Why does its oncology dominance matter more now for U.S. inves - AD HOC NEWS
AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study - TipRanks
AstraZeneca plc stock (GB0009895292): Is oncology dominance strong enough to unlock new upside? - AD HOC NEWS
32,091 Shares in Astrazeneca Plc $AZN Bought by Third View Private Wealth LLC - MarketBeat
AstraZeneca Adds to Demands on Hospitals Seeking Drug Discounts - Bloomberg Law News
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
Yousif Capital Management LLC Decreases Stake in Astrazeneca Plc $AZN - MarketBeat
Hardman Johnston Global Advisors LLC Reduces Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca India to divest Bengaluru manufacturing site for INR 3,400 crore - Prop News Time
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):